Morgan Stanley Maintains Equal-Weight on HOOKIPA Pharma, Raises Price Target to $2.25
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on HOOKIPA Pharma (NASDAQ:HOOK) and raises the price target from $2 to $2.25.
June 05, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on HOOKIPA Pharma and raises the price target from $2 to $2.25.
The news of Morgan Stanley maintaining an Equal-Weight rating on HOOKIPA Pharma and raising the price target from $2 to $2.25 is likely to have a positive short-term impact on the stock price. The increased price target indicates that the analyst sees potential for the stock to grow in value, which may attract more investors and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100